https://www.selleckchem.com/pr....oducts/itacnosertib.
65; 95% CI 0.46, 0.85; I2 = 73.37%), severity/mortality (OR = 0.69; 95% CI 0.43, 0.95; I2 = 22.90%), transfer to the intensive care unit among COVID-19 patients with hypertension (OR = 0.36, 95% CI 0.19, 0.53, I2 = 0.00%), hospitalization (OR = 0.79; 95% CI 0.60, 0.98; I2 = 0.00%), and acute respiratory distress syndrome (OR = 0.71; 95% CI 0.46, 0.95; I2 = 0.00%). The use of RAAS inhibitor was not associated with increased mortality or disease severity in COVID-19 patients. This study supports the current guidelines that disco
Like
Comment
Share
